A critical component of global influenza pandemic preparedness is the production of vaccine seed viruses representative of circulating zoonotic viruses. Vaccine seed viruses have been used to create H5, H9, and H7 vaccine lots that have been deployed to national stockpiles and/or clinical trials. This resource provides GMP-quality vaccine seed viruses for zoonotic influenza. For information on available strains, please see http://www.who.int/influenza/vaccines/virus/candidates_reagents/home/en/index.html.
Vaccine seed viruses are developed by St. Jude Children’s Research Hospital (SJCRH), one of the NIAID Centers of Excellence for Influenza Research and Surveillance. The production and dissemination of these seed viruses is coordinated by the World Health Organization (WHO) through their Global Influenza Surveillance and Response System program, of which the NIAID contractors at SJCRH are major participants.
Requestors should contact Dr. Richard Webby, Richard.email@example.com, SJCRH for GMP vaccine strain references. SJCRH will require the requestor to provide documentation that the receiving site has the appropriate importation documents, laboratory, and permits for receiving the material. SJCRH will work with NIAID to review the request. If the request is approved, SJCRH will ship the material on behalf of NIAID/NIH.
Last Updated February 11, 2014